Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $114M | $156K | $95.0K | $22.0K | $0.00 |
| Revenue growth | — | — | — | — | -99.9% | -39.1% | -76.8% | -100.0% |
| Operating income | -$193M | -$202M | -$258M | -$180M | -$336M | -$328M | -$273M | -$209M |
| Operating margin | — | — | — | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — |
| Net income | -$212M | -$185M | -$250M | -$182M | -$340M | -$327M | -$258M | -$191M |
| Net margin | — | — | — | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
| EPS (diluted) | -$7.31 | -$1.83 | -$2.08 | -$1.34 | -$2.38 | -$2.09 | -$1.32 | -$0.87 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$44.7M | -$137M | -$115M | -$185M | -$221M | -$238M | -$200M | -$149M |
| Capital expenditures | $3.23M | $50.8M | $66.0M | $21.4M | $5.19M | $1.52M | $694K | $386K |
| Free cash flow | -$47.9M | -$188M | -$181M | -$206M | -$226M | -$239M | -$201M | -$150M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $92.4M | $175M | $183M | $173M | $84.5M | $83.2M | $75.2M | $51.7M |
| Total assets | $774M | $718M | $1.23B | $1.04B | $978M | $643M | $549M | $416M |
| Total liabilities | $70.7M | $88.8M | $148M | $122M | $113M | $131M | $127M | $123M |
| Shareholders' equity | $703M | $629M | $1.01B | $925M | $667M | $512M | $422M | $293M |
| Retained earnings | -$212M | -$396M | -$646M | -$895M | -$973M | -$1.56B | -$1.82B | -$2.01B |
| Shares (wtd avg diluted) | 121M | 101M | 120M | 136M | 143M | 157M | 195M | 221M |
Every figure is extracted from Allogene Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.